Acquisition of early diagnostic markers for bladder cancer using urinary antibodies and examination for development of diagnostic kits

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07738
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Kitasato University
• Principal Investigator: Nagashio Ryo 北里大学, 医療衛生学部, 教授 (40618568)
• Co-Investigator(Kenkyū-buntansha): 朽津 有紀 北里大学, 医療衛生学部, 助教 (70878272)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 膀胱がん / 診断マーカー / 尿中抗体 / 二次元電気泳動法

Outline of Final Research Achievements

Aiming to obtain markers that can detect early-stage bladder cancer, we performed proteomic analysis using antibodies in the urine of bladder cancer patients. As a result of two-dimensional immunoblotting using the antibody in urine as the primary antibody, it was clarified that many antibodies recognizing various proteins derived from bladder cancer cells were contained. Among these antibodies, there are also antibodies commonly found in more than 70% of patients, suggesting their usefulness as a new marker for bladder cancer.

Free Research Field

抗体基盤の疾患プロテオミクス

Academic Significance and Societal Importance of the Research Achievements

本研究では無侵襲性である尿に着目し、膀胱がん細胞由来のタンパク質を抗原とする尿中抗体を検出した。検出された抗体の抗原を同定し、膀胱がんの診断マーカーとして実用化することで、検診などに使用可能な膀胱がん診断用簡易検査キットの開発が可能となる。その結果、自覚症状のない状態での発見が困難な膀胱がん患者の早期診断が可能となり、患者のQOL向上や医療費の削減などにつながるため社会的意義は大きい。